Paper39273237
Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.
Raghav A and 1 other. Int J Mol Sci, 2024. Cited by 2 papers, by iCite.
Cite this record
ConductScience Library. Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies. Papers, record 39273237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39273237
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Phase I-IV Drug Trials on Hepatocellular Carcinoma in Asian Populations: A Systematic Review of Ten Years of Studies.
- PubMed
Topics13
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Carcinoma, Hepatocellular | Major topic |
| Liver Neoplasms | Major topic |
| Humans | |
| Antibodies, Monoclonal, Humanized | |
| Antineoplastic Agents | |
| Antineoplastic Combined Chemotherapy Protocols | |
| Asian People | |
| Bevacizumab | |
| Phenylurea Compounds | |
| Quinolines | |
| Randomized Controlled Trials as Topic | |
| Sorafenib | |
| Clinical Trials as Topic |
Source PubMed
References102
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 21354226 | Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma. | J Hepatol | 2011 | https://conductscience.org/library/papers/21354226 | PubMed |
| 2 | 14667750 | Hepatocellular carcinoma. | Lancet | 2003 | https://conductscience.org/library/papers/14667750 | PubMed |
| 3 | 23980090 | Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. | J Clin Oncol | 2013 | https://conductscience.org/library/papers/23980090 | PubMed |
| 4 | 30843325 | Diagnostic and prognostic biomarkers in cholangiocarcinoma. | Liver Int | 2019 | https://conductscience.org/library/papers/30843325 | PubMed |
| 5 | 18650514 | Sorafenib in advanced hepatocellular carcinoma. | N Engl J Med | 2008 | https://conductscience.org/library/papers/18650514 | PubMed |
| 6 | 30665869 | Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial. | Lancet Oncol | 2019 | https://conductscience.org/library/papers/30665869 | PubMed |
| 7 | 18852116 | Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. | Mol Cancer Ther | 2008 | https://conductscience.org/library/papers/18852116 | PubMed |
| 8 | 33087333 | Camrelizumab in Combination with Apatinib in Patients with Advanced Hepatocellular Carcinoma (RESCUE): A Nonrandomized, Open-label, Phase II Trial. | Clin Cancer Res | 2021 | https://conductscience.org/library/papers/33087333 | PubMed |
| 9 | 25294897 | A phase II study of the efficacy and safety of the combination therapy of the MEK inhibitor refametinib (BAY 86-9766) plus sorafenib for Asian patients with unresectable hepatocellular carcinoma. | Clin Cancer Res | 2014 | https://conductscience.org/library/papers/25294897 | PubMed |
| 10 | 34087115 | Lenvatinib versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma: patient-reported outcomes from a randomised, open-label, non-inferiority, phase 3 trial. | Lancet Gastroenterol Hepatol | 2021 | https://conductscience.org/library/papers/34087115 | PubMed |
| 11 | 34914889 | Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial. | Lancet Oncol | 2022 | https://conductscience.org/library/papers/34914889 | PubMed |
| 12 | 36353563 | Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis. | Front Oncol | 2022 | https://conductscience.org/library/papers/36353563 | PubMed |
| 13 | 31024205 | Hepatocellular Carcinoma: Etiology and Current and Future Drugs. | J Clin Exp Hepatol | 2019 | https://conductscience.org/library/papers/31024205 | PubMed |
| 14 | 31060120 | 2018 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. | Gut Liver | 2019 | https://conductscience.org/library/papers/31060120 | PubMed |
| 15 | 34902530 | Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. | J Hepatol | 2022 | https://conductscience.org/library/papers/34902530 | PubMed |
| 16 | 23340295 | Contribution of OATP1B1 and OATP1B3 to the disposition of sorafenib and sorafenib-glucuronide. | Clin Cancer Res | 2013 | https://conductscience.org/library/papers/23340295 | PubMed |
| 17 | 19095497 | Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. | Lancet Oncol | 2009 | https://conductscience.org/library/papers/19095497 | PubMed |
| 18 | 32847838 | Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial. | ESMO Open | 2020 | https://conductscience.org/library/papers/32847838 | PubMed |
| 19 | 21399234 | Recent advances in anti-angiogenic therapy of cancer. | Oncotarget | 2011 | https://conductscience.org/library/papers/21399234 | PubMed |
| 20 | 28434648 | Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. | Lancet | 2017 | https://conductscience.org/library/papers/28434648 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 2 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42639780 | Efficacy and safety of Heshu Xiaoji pills combined with standard treatment strategy in hepatitis B virus-related hepatocellular carcinoma: a single-center, open-label, prospective controlled, real-world cohort study. | J Tradit Chin Med | 2026 | https://conductscience.org/library/papers/42639780 | PubMed |
| 40647587 | Drug-Induced Autoimmune Hepatitis: Robust Causality Assessment Using Two Different Validated and Scoring Diagnostic Algorithms. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/40647587 | PubMed |
| 39781529 | The Red Cell Distribution Width to Albumin Ratio: A Novel Prognostic Indicator in Hepatitis B Virus-Related Hepatocellular Carcinoma. | Int J Med Sci | 2025 | https://conductscience.org/library/papers/39781529 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39273237
GET https://conductscience.org/api/papers/v1/39273237/references?page=2